{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:05:51Z","timestamp":1767953151121,"version":"3.49.0"},"reference-count":67,"publisher":"Termedia Sp. z.o.o.","issue":"2","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Immunol"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is still burdened with high mortality (5-year survival rate &lt; 9%) due to late diagnosis, aggressiveness, and a\u00a0lack of more effective treatment methods. Early diagnosis and new therapeutic approaches based on the reprogrammed metabolism of the tumor in a\u00a0nutrient-deficient environment are expected to improve the future treatment of PDAC patients. Research results suggest that genetic and metabolic disorders may precede the onset of neoplastic changes, which should allow for earlier appropriate treatment. Glycolysis and glutaminolysis are the most investigated pathways associated with the highest aggressiveness of pancreatic tumors. Blocking of selected metabolic pathways related to the local adaptive metabolic activity of pancreatic cancer cells improving nutrient acquisition and metabolic crosstalk within the microenvironment to sustain proliferation may inhibit cancer development, increase cancer cells death, and increase sensitivity to other forms of treatment (e.g., chemotherapy). Depriving cancer cells of important nutrients (glucose, glutamine) revealed tumor \u201ccheckpoints\u201d for the mechanisms that drive cell proliferation and metastasis formation in order to determine its accuracy for individualization of the therapeutic approach. The present review highlights selected metabolic signaling pathways and their regulators aimed at inhibiting the neoplastic process. Particular attention has been paid to the adaptive metabolism of pancreatic cancer, which promotes its development in an oxygen-deficient and nutrient-poor environment.<\/jats:p>","DOI":"10.5114\/ceji.2021.107027","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T04:42:22Z","timestamp":1631767342000},"page":"258-263","source":"Crossref","is-referenced-by-count":4,"title":["Molecular aspects of pancreatic cancer: focus on reprogrammed metabolism in a nutrient-deficient environment and potential therapeutic targets"],"prefix":"10.5114","volume":"46","author":[{"given":"Robert","family":"S\u0142otwi\u0144ski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustaw","family":"Lech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia Ma\u0142gorzata","family":"S\u0142otwi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"ref-1541777","first-page":"7","article-title":"Cancer statistics 2020","volume":"70","author":"Siegel RL","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020): Cancer statistics 2020. CA Cancer J Clin 70: 7-30.","journal-title":"CA Cancer J Clin"},{"key":"ref-1541778","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2019.11.002","article-title":"Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma","volume":"125","author":"Latenstein AEJ","year":"2020","unstructured":"Latenstein AEJ, Geest LGM, Bonsing BA, et al. (2020): Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer 125: 83-93.","journal-title":"Eur J Cancer"},{"key":"ref-1541779","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2015.08.006","article-title":"State of the art and future directions of pancreatic ductal adenocarcinoma therapy","volume":"155","author":"Neuzillet C","year":"2015","unstructured":"Neuzillet C, Tijeras-Raballand A, Bourget P, et al. (2015): State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther 155: 80-104.","journal-title":"Pharmacol Ther"},{"key":"ref-1541780","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla P","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V (2019): Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10: 10-27.","journal-title":"World J Oncol"},{"key":"ref-1541781","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/gutjnl-2017-314828","article-title":"Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations","volume":"68","author":"Huang L","year":"2019","unstructured":"Huang L, Jansen L, Balavarca Y, et al. (2019): Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 68: 130-139.","journal-title":"Gut"},{"key":"ref-1541782","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12916-018-1120-9","article-title":"Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study","volume":"16","author":"Huang L","year":"2018","unstructured":"Huang L, Jansen L, Balavarca Y, et al. (2018): Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Medicine 16: 125 (http:\/\/creativecommons.org\/licenses\/by\/4.0\/)","journal-title":"BMC Medicine"},{"key":"ref-1541783","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/01.sla.0000245845.06772.7d","article-title":"Surgery for recurrent pancreatic ductal adenocarcinoma","volume":"245","author":"Kleeff J","year":"2007","unstructured":"Kleeff J, Reiser C, Hinz U, et al. (2007) Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 245: 566-572.","journal-title":"Ann Surg"},{"key":"ref-1541784","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"The Groupe Tumours Digestives of Unicancer and the PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy T","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. (2011): The Groupe Tumours Digestives of Unicancer and the PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.","journal-title":"N Engl J Med"},{"key":"ref-1541785","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris HA III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J, et al. (1997): Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.","journal-title":"J Clin Oncol"},{"key":"ref-1541786","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore MJ","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, et al. (2007): Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.","journal-title":"J Clin Oncol"},{"key":"ref-1541787","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2020.38.15_suppl.4515","article-title":"Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region","volume":"38","author":"Reni M","year":"2020","unstructured":"Reni M, Riess H, O\u2019Reilly EM, et al. (2020): Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region. J Clin Oncol 38: 15 suppl.: 4515-4515 (https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01964430?view=results).","journal-title":"J Clin Oncol"},{"key":"ref-1541788","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son J","year":"2013","unstructured":"Son J, Lyssiotis CA, Ying H, et al. (2013): Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496: 101-105.","journal-title":"Nature"},{"key":"ref-1541789","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/aps.2010.151","article-title":"The role of p53 in cell metabolism","volume":"31","author":"Zhang XD","year":"2010","unstructured":"Zhang XD, Qin ZH, Wang J (2010): The role of p53 in cell metabolism. Acta Pharmacol Sin 31: 1208-1212.","journal-title":"Acta Pharmacol Sin"},{"key":"ref-1541790","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2017.04.029","article-title":"GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells","volume":"400","author":"Abrego J","year":"2017","unstructured":"Abrego J, Gunda V, Vernucci E, et al. (2017): GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Cancer Lett 400: 37-46.","journal-title":"Cancer Lett"},{"key":"ref-1541791","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti MV","year":"2016","unstructured":"Liberti MV, Locasale JW (2016): The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41: 211-218.","journal-title":"Trends Biochem Sci"},{"key":"ref-1541792","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1023\/B:DDAS.0000037803.32013.aa","article-title":"Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer","volume":"49","author":"Ventrucci M","year":"2004","unstructured":"Ventrucci M, Cipolla A, Racchini C, et al. (2004): Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 49: 1149-1155.","journal-title":"Dig Dis Sci"},{"key":"ref-1541793","doi-asserted-by":"crossref","first-page":"109521","DOI":"10.1016\/j.biopha.2019.109521","article-title":"Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine","volume":"121","author":"Dai S","year":"2020","unstructured":"Dai S, Penga Y, Zhu Y, et al. (2020): Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Biomed Pharmacother 121: 109521.","journal-title":"Biomed Pharmacother"},{"key":"ref-1541794","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1080\/15384101.2020.1796036","article-title":"Low glucose enhanced metformin\u2019s inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via upregulation of miR-210-5p","volume":"19","author":"Ma M","year":"2020","unstructured":"Ma M, Ma C, Li P, et al. (2020): Low glucose enhanced metformin\u2019s inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via upregulation of miR-210-5p. Cell Cycle 19: 2168-2181.","journal-title":"Cell Cycle"},{"key":"ref-1541809","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3390\/cancers11101496","article-title":"Targeting glycolysis with epigallocatechin-3-gallate enhances the efficacy of chemotherapeutics in pancreatic cancer cells and xenografts","volume":"11","author":"Wei R","year":"2019","unstructured":"Wei R, Hackman RM, Wang Y, Mackenzie GG (2019): Targeting glycolysis with epigallocatechin-3-gallate enhances the efficacy of chemotherapeutics in pancreatic cancer cells and xenografts. Cancers 11: 1496.","journal-title":"Cancers"},{"key":"ref-1541827","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4251\/wjgo.v7.i10.250","article-title":"Genomic alterations in pancreatic cancer and their relevance to therapy","volume":"7","author":"Takai E","year":"2015","unstructured":"Takai E, Yachida S (2015): Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol 7: 250-258.","journal-title":"World J Gastrointest Oncol"},{"key":"ref-1541844","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbcan.2018.04.011","article-title":"The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance","volume":"1870","author":"Biancur DE","year":"2018","unstructured":"Biancur DE, Kimmelman AC (2018): The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochim Biophys Acta Rev Cancer 1870: 67-75.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref-1541846","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nature09515","article-title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","volume":"467","author":"Yachida S","year":"2010","unstructured":"Yachida S, Jones S, Bozic I, et al. (2010): Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.","journal-title":"Nature"},{"key":"ref-1541847","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1053\/j.gastro.2020.02.059","article-title":"Carcinogenesis of pancreatic ductal adenocarcinoma","volume":"158","author":"Storz P","year":"2020","unstructured":"Storz P, Crawford HC (2020): Carcinogenesis of pancreatic ductal adenocarcinoma. Gastroenterology 158: 2072-2081.","journal-title":"Gastroenterology"},{"key":"ref-1541848","first-page":"358","article-title":"Pancreatic adenocarcinoma pathology: changing \u201clandscape\u201d","volume":"6","author":"Brosens LAA","year":"2015","unstructured":"Brosens LAA, Hackeng WM, Offerhaus GJ, et al. (2015): Pancreatic adenocarcinoma pathology: changing \u201clandscape\u201d. J Gastrointest Oncol 6: 358-374.","journal-title":"J Gastrointest Oncol"},{"key":"ref-1541849","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre AJ","year":"2018","unstructured":"Aguirre AJ, Nowak JA, Camarda ND, et al. (2018): Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov 8: 1096-1111.","journal-title":"Cancer Discov"},{"key":"ref-1541850","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signalling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones S","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, et al. (2008): Core signalling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.","journal-title":"Science"},{"key":"ref-1541851","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/nm.3686","article-title":"Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development","volume":"20","author":"Mayers JR","year":"2014","unstructured":"Mayers JR, Wu C, Clish CB, et al. (2014): Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 20: 1193-1198.","journal-title":"Nat Med"},{"key":"ref-1541852","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.21873\/anticanres.13314","article-title":"Towards a personalized approach in pancreatic cancer diagnostics through plasma amino acid analysis","volume":"39","author":"Tumas J","year":"2019","unstructured":"Tumas J, Baskirova I, Petrenas T, et al. (2019): Towards a personalized approach in pancreatic cancer diagnostics through plasma amino acid analysis. Anticancer Res 39: 2035-2042.","journal-title":"Anticancer Res"},{"key":"ref-1541853","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","article-title":"The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression","volume":"95","author":"Vaupel P","year":"2019","unstructured":"Vaupel P, Schmidberger H, Mayer A (2019): The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol 95: 912-919.","journal-title":"Int J Radiat Biol"},{"key":"ref-1541854","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/dna.2019.5089","article-title":"Glycolysis-based genes associated with the clinical outcome of pancreatic ductal adenocarcinoma identified by the cancer genome atlas data analysis","volume":"39","author":"Tian G","year":"2020","unstructured":"Tian G, Li G, Liu P, et al. (2020): Glycolysis-based genes associated with the clinical outcome of pancreatic ductal adenocarcinoma identified by the cancer genome atlas data analysis. DNA Cell Biol 39: 417-427.","journal-title":"DNA Cell Biol"},{"key":"ref-1541855","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature25459","article-title":"Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes","volume":"554","author":"Mueller S","year":"2018","unstructured":"Mueller S, Engleitner T, Maresch R, et al. (2018): Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 554: 62-68.","journal-title":"Nature"},{"key":"ref-1541856","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon J","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, et al. (2019): The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575: 217-223.","journal-title":"Nature"},{"key":"ref-1541857","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.seminoncol.2017.10.004","article-title":"Metabolic coupling and the reverse Warburg effect in cancer: implications for novel biomarker and anticancer agent development","volume":"44","author":"Wilde L","year":"2017","unstructured":"Wilde L, Roche M, Domingo-Vidal M, et al. (2017): Metabolic coupling and the reverse Warburg effect in cancer: implications for novel biomarker and anticancer agent development. Semin Oncol 44: 198-203.","journal-title":"Semin Oncol"},{"key":"ref-1541858","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bbrc.2019.06.096","article-title":"P4HA1\/HIF1 feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer","volume":"516","author":"Cao X","year":"2019","unstructured":"Cao X, Cao Y, Li W, et al. (2019): P4HA1\/HIF1 feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer. Biochem Biophys Res Commun 516: 606-612.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref-1541859","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.7150\/jca.21125","article-title":"The glycolytic switch in tumors: how many players are involved?","volume":"8","author":"Yu L","year":"2017","unstructured":"Yu L, Chen X, Sun X, et al. (2017): The glycolytic switch in tumors: how many players are involved? J Cancer 8: 3430-3440.","journal-title":"J Cancer"},{"key":"ref-1541860","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1073\/pnas.1307237110","article-title":"Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids","volume":"110","author":"Kamphorst JJ","year":"2013","unstructured":"Kamphorst JJ, Cross JR, Fan J, et al. (2013): Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci USA 110: 8882-8887.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref-1541861","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000104457","article-title":"Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics","volume":"53","author":"Airley RE","year":"2007","unstructured":"Airley RE, Mobasheri A (2007): Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53: 233-256.","journal-title":"Chemotherapy"},{"key":"ref-1541862","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jcp.20166","article-title":"Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer","volume":"202","author":"Macheda ML","year":"2005","unstructured":"Macheda ML, Rogers S, Best JD (2005): Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202: 654-662.","journal-title":"J Cell Physiol"},{"key":"ref-1541863","doi-asserted-by":"crossref","first-page":"19760","DOI":"10.18632\/oncotarget.15035","article-title":"Prognostic value of GLUT-1 expression in pancreatic cancer: Results from 538 patients","volume":"8","author":"Sharen G","year":"2017","unstructured":"Sharen G, Peng Y, Cheng H, et al. (2017): Prognostic value of GLUT-1 expression in pancreatic cancer: Results from 538 patients. Oncotarget 8: 19760-19767.","journal-title":"Oncotarget"},{"key":"ref-1541864","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1186\/s12885-020-07409-9","article-title":"GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival","volume":"20","author":"Boira MA","year":"2020","unstructured":"Boira MA, Di Martino M, Gordillo C, et al. (2020): GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival. BMC Cancer 20: 909.","journal-title":"BMC Cancer"},{"key":"ref-1541865","doi-asserted-by":"crossref","first-page":"6214838","DOI":"10.1155\/2018\/6214838","article-title":"Glucose and lactate transport in pancreatic cancer: glycolytic metabolism revisited","volume":"2018","author":"Cameron ME","year":"2018","unstructured":"Cameron ME, Yakovenko A, Trevino JG (2018): Glucose and lactate transport in pancreatic cancer: glycolytic metabolism revisited. J Oncol 2018: 6214838.","journal-title":"J Oncol"},{"key":"ref-1541866","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/MPA.0000000000000571","article-title":"Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells","volume":"45","author":"Kong SC","year":"2016","unstructured":"Kong SC, N\u00f8hr-Nielsen A, Zeeberg K, et al. (2016): Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells. Pancreas 45: 1036-1047.","journal-title":"Pancreas"},{"key":"ref-1541867","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza GL","year":"2010","unstructured":"Semenza GL (2010): Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.","journal-title":"Oncogene"},{"key":"ref-1541868","doi-asserted-by":"crossref","first-page":"e1026535","DOI":"10.1080\/2162402X.2015.1026535","article-title":"HIF-1 is a critical target of pancreatic cancer","volume":"4","author":"Hao J","year":"2015","unstructured":"Hao J (2015): HIF-1 is a critical target of pancreatic cancer. Oncoimmunology 4: e1026535.","journal-title":"Oncoimmunology"},{"key":"ref-1541869","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0002-9440(10)63924-7","article-title":"Dominant-negative hypoxia-inducible factor-1\u03b1 reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism","volume":"162","author":"Chen J","year":"2003","unstructured":"Chen J, Zhao S, Nakada K, et al. (2003): Dominant-negative hypoxia-inducible factor-1\u03b1 reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 162: 1283-1291.","journal-title":"Am J Pathol"},{"key":"ref-1541870","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","article-title":"MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer","volume":"32","author":"Shukla SK","year":"2017","unstructured":"Shukla SK, Purohit V, Mehla K, et al. (2017): MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell 32: 71-87.","journal-title":"Cancer Cell"},{"key":"ref-1541871","doi-asserted-by":"crossref","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis RJ","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS (2016): Fundamentals of cancer metabolism. Sci Adv 2: e1600200.","journal-title":"Sci Adv"},{"key":"ref-1541872","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns RA","year":"2011","unstructured":"Cairns RA, Harris IS, Mak TW (2011): Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.","journal-title":"Nat Rev Cancer"},{"key":"ref-1541873","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/abbs\/gmw097","article-title":"Energy sources identify metabolic phenotypes in pancreatic cancer","volume":"48","author":"Liang C","year":"2016","unstructured":"Liang C, Qin Y, Zhang B, et al. (2016): Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochim Biophys Sin 48: 969-979.","journal-title":"Acta Biochim Biophys Sin"},{"key":"ref-1541874","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ccell.2016.12.006","article-title":"Employing metabolism to improve the diagnosis and treatment of pancreatic cancer","volume":"31","author":"Halbrook CJ","year":"2017","unstructured":"Halbrook CJ, Lyssiotis CA (2017): Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell 31: 5-19.","journal-title":"Cancer Cell"},{"key":"ref-1541875","doi-asserted-by":"crossref","first-page":"e1065","DOI":"10.1038\/cddis.2014.38","article-title":"Metabolism addiction in pancreatic cancer","volume":"5","author":"Blum R","year":"2014","unstructured":"Blum R, Kloog Y (2014): Metabolism addiction in pancreatic cancer. Cell Death Dis 5: e1065.","journal-title":"Cell Death Dis"},{"key":"ref-1541876","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fphys.2018.00335","article-title":"Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics","volume":"9","author":"Murthy D","year":"2018","unstructured":"Murthy D, Attri KS, Singh PK (2018): Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics. Front Physiol 9: 335.","journal-title":"Front Physiol"},{"key":"ref-1541877","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/jcmm.13202","article-title":"HIF-2a regulates non-canonical glutamine metabolism via activation of PI3K\/mTORC2 pathway in human pancreatic ductal adenocarcinoma","volume":"21","author":"Li W","year":"2017","unstructured":"Li W, Chen C, Zhao X, et al. (2017): HIF-2a regulates non-canonical glutamine metabolism via activation of PI3K\/mTORC2 pathway in human pancreatic ductal adenocarcinoma. J Cell Mol Med 21: 2896-2908.","journal-title":"J Cell Mol Med"},{"key":"ref-1541878","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/or.2016.4820","article-title":"Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K\/Akt pathway via Polo-like kinase 1","volume":"36","author":"Mao Y","year":"2016","unstructured":"Mao Y, Xi L, Li Q, et al. (2016): Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K\/Akt pathway via Polo-like kinase 1. Oncol Rep 36: 49-56.","journal-title":"Oncol Rep"},{"key":"ref-1541879","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics","volume":"6","author":"Akinleye A","year":"2013","unstructured":"Akinleye A, Avvaru P, Furqan M, et al. (2013): Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 6: 88.","journal-title":"J Hematol Oncol"},{"key":"ref-1541880","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cmet.2019.11.020","article-title":"A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells","volume":"31","author":"Yoo HC","year":"2020","unstructured":"Yoo HC, Park SJ, Nam M, et al. (2020): A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab 31: 267-283.","journal-title":"Cell Metab"},{"key":"ref-1541881","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.7150\/jca.28299","article-title":"AMPK inhibition suppresses the malignant phenotype of pancreatic cancer cells in part by attenuating aerobic glycolysis","volume":"10","author":"Hu M","year":"2019","unstructured":"Hu M, Chen X, Ma L, et al. (2019): AMPK inhibition suppresses the malignant phenotype of pancreatic cancer cells in part by attenuating aerobic glycolysis. J Cancer 10: 1870-1878.","journal-title":"J Cancer"},{"key":"ref-1541882","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.omto.2019.07.005","article-title":"ROS\/KRAS\/AMPK signaling contributes to gemcitabine-induced stem-like cell properties in pancreatic cancer","volume":"14","author":"Zhao H","year":"2019","unstructured":"Zhao H, Wu S, Li H, et al. (2019): ROS\/KRAS\/AMPK signaling contributes to gemcitabine-induced stem-like cell properties in pancreatic cancer. Mol Ther Oncolytics 14: 299-312.","journal-title":"Mol Ther Oncolytics"},{"key":"ref-1541883","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.csbj.2018.07.003","article-title":"Biophysics of tumor microenvironment and cancer metastasis\u2013a mini review","volume":"16","author":"Emon B","year":"2018","unstructured":"Emon B, Bauer J, Jain Y, et al. (2018): Biophysics of tumor microenvironment and cancer metastasis\u2013a mini review. Comput Struct Biotechnol J 16: 279-287.","journal-title":"Comput Struct Biotechnol J"},{"key":"ref-1541884","doi-asserted-by":"crossref","first-page":"15965","DOI":"10.1038\/ncomms15965","article-title":"Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism","volume":"8","author":"Biancur DE","year":"2017","unstructured":"Biancur DE, Paulo JA, Ma\u0142achowska B, et al. (2017): Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat Commun 8: 15965.","journal-title":"Nat Commun"},{"key":"ref-1541885","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway","volume":"496","author":"Son J","year":"2013","unstructured":"Son J, Lyssiotis CA, Ying H, et al. (2013): Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway. Nature 496: 101-105.","journal-title":"Nature"},{"key":"ref-1541886","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41419-017-0089-1","article-title":"Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition","volume":"9","author":"Yang S","year":"2018","unstructured":"Yang S, Hwang S, Kim M, et al. (2018): Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition. Cell Death Dis 9: 55.","journal-title":"Cell Death Dis"},{"key":"ref-1541887","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrc3057","article-title":"Pro-senescence therapy for cancer treatment","volume":"11","author":"Nardella C","year":"2011","unstructured":"Nardella C, Clohessy JG, Alimonti A, Pandolfi PP (2011): Pro-senescence therapy for cancer treatment. Nat Rev Cancer 11: 503-511.","journal-title":"Nat Rev Cancer"},{"key":"ref-1541888","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc2772","article-title":"Senescence in tumours: evidence from mice and humans","volume":"10","author":"Collado M","year":"2010","unstructured":"Collado M, Serrano M (2010): Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10: 51-57.","journal-title":"Nat Rev Cancer"},{"key":"ref-1541889","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.3390\/cancers12102976","article-title":"FGFR4 inhibitor BLU9931 attenuates pancreatic cancer cell proliferation and invasion while inducing senescence: evidence for senolytic therapy potential in pancreatic cancer","volume":"12","author":"Sasaki N","year":"2020","unstructured":"Sasaki N, Gomi F, Yoshimura H, et al. (2020): FGFR4 inhibitor BLU9931 attenuates pancreatic cancer cell proliferation and invasion while inducing senescence: evidence for senolytic therapy potential in pancreatic cancer. Cancers 12: 2976.","journal-title":"Cancers"},{"key":"ref-1541890","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying H","year":"2012","unstructured":"Ying H, Kimmelman AC, Lyssiotis CA, et al. (2012): Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149: 656-670.","journal-title":"Cell"},{"key":"ref-1541891","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41467-019-08759-0","article-title":"MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1","volume":"10","author":"Yang Y","year":"2020","unstructured":"Yang Y, Gabra MBI, Hanse EA, et al. (2020): MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1. Nat Commun 10: 809.","journal-title":"Nat Commun"}],"container-title":["Central European Journal of Immunology"],"original-title":[],"link":[{"URL":"https:\/\/ceji.termedia.pl\/pdf-135599-129717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ceji.termedia.pl\/pdf-135599-129717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:33:49Z","timestamp":1767947629000},"score":1,"resource":{"primary":{"URL":"https:\/\/ceji.termedia.pl\/Molecular-aspects-of-pancreatic-cancer-focus-on-reprogrammed-metabolism-in-a-nutrient,135599,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"alternative-id":["135599"],"URL":"https:\/\/doi.org\/10.5114\/ceji.2021.107027","relation":{},"ISSN":["1426-3912","1644-4124"],"issn-type":[{"value":"1426-3912","type":"print"},{"value":"1644-4124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]}}}